Published March 9, 2023 | Version v1
Journal article

Mid-Infrared Spectroscopy as a New Tool for Ruling Out Spontaneous Bacterial Peritonitis: A Proof-of-Concept Study

Others:
Laboratoire d'Ingénierie des Matériaux de Bretagne (LIMATB) ; Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Institut Brestois du Numérique et des Mathématiques (IBNM) ; Université de Brest (UBO)-Université de Brest (UBO)
Hepatology ; Hopital
Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale (EA7479 SPURBO) ; Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM) ; Université de Brest (UBO)-Université de Brest (UBO)
Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS)
Nutrition, Métabolismes et Cancer (NuMeCan) ; Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (INRAE)
DIAFIR
Laboratoire Universitaire des Sciences Appliquées de Cherbourg (LUSAC) ; Université de Caen Normandie (UNICAEN) ; Normandie Université (NU)-Normandie Université (NU)
Institut National de la Santé et de la Recherche Médicale (INSERM)
Pôle Digestif ; Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet
CHU Saint-Antoine [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Centre Méditerranéen de Médecine Moléculaire (C3M) ; Université de Nice Sophia-Antipolis (UNSA)
COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)
UMR_ S- 1065, C3M ; Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre méditerranéen de médecine moléculaire (C3M) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UniCA)
ANR-11-LABX-0028,SIGNALIFE,Réseau d'Innovation sur les Voies de Signalisation en Sciences de la Vie(2011)
ANR-15-IDEX-0001,UCA JEDI,Idex UCA JEDI(2015)
ANR-18-CE14-0019,INFLAMMASYK,Etude de la signalisation SYK dans les maladies inflammatoires chroniques(2018)
ANR-19-CE14-0044,MATRIXNASH,Impact des interactions cellulo-matricielles anormales dans progression des hépatopathies métaboliques(2019)

Description

Background and aims: A highly sensitive and specific point-of-care method for diagnosing spontaneous bacterial peritonitis (SBP) is currently lacking. The objective of the present study is to evaluate the diagnostic value of a rapid, easy-to-use, mid-infrared fiber evanescent wave spectroscopy (MIR-FEWS) method for ruling out SBP. Patients and Methods: Cirrhotic patients (n = 256) at five centers in France were included for suspected SBP or for the scheduled evacuation of ascites fluid. The mid-infrared spectrum of 7 µL of an ascites fluid sample was recorded using a MIR-FEWS system. To define a model for the diagnosis of SBP, the patients were divided into a calibration group (n = 170) and a validation group (n = 86). Results: Most of the patients were male (71%). The mean age was 60.25 years. Alcohol-related liver disease was the most common cause of cirrhosis. SBP was observed in 18% of the patients. For the diagnosis of SBP in the calibration and validation groups, respectively, the model gave areas under the receiver operating characteristic curves of 0.87 and 0.89, sensitivities of 90% and 87%, specificities of 78% and 80%, positive predictive values of 48% and 50%, negative predictive values of 97% and 96%, positive likelihood ratio of 4.09 and 4.35, negative likelihood ratio of 0.13 and 0.16, Youden index of 0.68 and 0.67, and correct classification rates of 80% and 81%. Conclusion: The results of this proof-of-concept study show that MIR-FEWS is a highly sensitive diagnostic method for ruling out SBP. The method warrants further investigation.

Abstract

International audience

Additional details

Created:
March 10, 2024
Modified:
March 10, 2024